We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
LyRIC indeterminate response and Immune‐mediated pseudoprogression of diffuse large B‐cell lymphoma following polatuzumab‐based salvage therapy.
- Authors
Lee, Alexander T. J.; Attygale, Ayoma D.; Sharma, Rajaei K.; Iyengar, Sunil; El‐Sharkawi, Dima; Chau, Ian; Vroobel, Katherine M.; Fotiadis, Nicos; Khan, Nasir; Butterfield, Nicholas; Wotherspoon, Andrew; Cunningham, David; Sharma, Bhupinder
- Abstract
LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy Keywords: diffuse large B cell lymphoma; polatuzumab; pseudo-progression EN diffuse large B cell lymphoma polatuzumab pseudo-progression e248 e251 4 06/18/20 20200615 NES 200615 To the editor Sehn I et al. i [1] recently reported the results of a randomised phase II clinical trial that demonstrated a significant and clinically meaningful improvement of overall survival in transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) when the CD79b-targeting antibody-drug conjugate (ADC) polatuzumab vedotin (PV) was added to a standard chemoimmunotherapy backbone of bendamustine (B) and rituximab (R). (H) Fused FDG-PET/CT images performed following the second cycle of PV + BR. gl Salvage chemoimmunotherapy with PV + BR was commenced and response assessment FDG-PET/CT was performed on cycle day 20.
- Subjects
DIFFUSE large B-cell lymphomas; SALVAGE therapy; LYMPHOMAS; ANTIBODY-dependent cell cytotoxicity; CORE needle biopsy
- Publication
British Journal of Haematology, 2020, Vol 189, Issue 6, pe248
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.16679